SCHEMBL336991

SCHEMBL336991

O=C(O)CC1CCC(=O)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.52
POLB P06746 1/20 0.52
MAPT P10636 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
SLC6A12 P48065 5/20 0.43
SLC6A11 P48066 5/20 0.43
SLC6A13 Q9NSD5 5/20 0.43
SLC6A1 P30531 2/20 0.43
GABRA5 P31644 2/20 0.43
GABRB2 P47870 2/20 0.43
GABRA1 P14867 1/20 0.43
GABRR1 P24046 1/20 0.43
GABRA4 P48169 1/20 0.43
ANPEP P15144 1/20 0.41
ENPEP Q07075 1/20 0.41
ITGB3 P05106 1/20 0.40
ITGB2 P05107 1/20 0.40
ITGB1 P05556 1/20 0.40
ITGAV P06756 1/20 0.40
ITGA2B P08514 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methylene Chloride SCHEMBL28174699 0.94 ALDH1A1 (0.52) ALDH1A1POLBMAPTTDP1SLC6A12
SCHEMBL2559145 0.86 ALDH1A1 (0.58) ALDH1A1POLBMAPTTDP1SLC6A12
SCHEMBL29954148 0.86 ALDH1A1 (0.58) ALDH1A1POLBMAPTTDP1SLC6A12
Ammonia Solution, Strong SCHEMBL28014494 0.85 ALDH1A1 (0.56) ALDH1A1POLBMAPTTDP1SLC6A12
SCHEMBL4194440 0.80 ALDH1A1 (0.47) ALDH1A1POLBMAPTTDP1SLC6A12
SCHEMBL16969212 0.80 FFAR4 (0.50) FFAR4FFAR1
SCHEMBL30659860 0.79 ALDH1A1 (0.50) ALDH1A1POLBMAPTTDP1SLC6A12
SCHEMBL13226914 0.79 TLR4 (0.36) ALDH1A1POLBMAPTTDP1AKR1C3
SCHEMBL14841474 0.79 HSD11B1 (0.35) ALDH1A1POLBMAPTTDP1DGAT1
SCHEMBL24197646 0.79 ANPEP (0.56) ALDH1A1POLBMAPTTDP1SLC6A12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-56092244-A None JP disclosed
US-12441761-B2 Conjugation reagents and methods using 1,2-cyclohexanediones Encodia, Inc. (US) 2025-10-14 US disclosed
US-20250236632-A1 BETA-LACTAMASE INHIBITORS VENATORX PHARMACEUTICALS INC (US) 2025-07-24 US disclosed
WO-2025049804-A2 AGENTS FOR THE TREATMENT OF NON-REPLICATING BACTERIA ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2025-03-06 WO disclosed
WO-2024192064-A1 COMPOUNDS AND COMPOSITIONS AS SMARCA2/4 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A/ PROTEOVANT THERAPEUTICS, INC. (US) 2024-09-19 WO disclosed
CN-118076581-A Iron death modulators, their preparation and use 维泰瑞隆有限公司 2024-05-24 CN disclosed
CN-118043471-A Process for the production of (1 r,4 r) -4-substituted cyclohexane-1-amines 吉瑞工厂 2024-05-14 CN disclosed
CN-112778183-B Nitrogen-containing ring derivative regulator, preparation method and application thereof 江苏豪森药业集团有限公司 2024-05-10 CN disclosed
WO-2023226950-A1 PEPTIDOMIMETIC STAT PROTEIN DEGRADER, COMPOSITION AND USE THEREOF 杭州和正医药有限公司 2023-11-30 WO disclosed
US-20230295222-A1 Conjugation Reagents and Methods Using 1,2-Cyclohexanediones Encodia, Inc. (US) 2023-09-21 US disclosed
US-6056895-A Fluorocyclohexane derivatives, and liquid-crystalline medium MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-05-02 US disclosed
EP-0993459-A1 COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE SCHERING CORPORATION (US) 2000-04-19 EP disclosed
WO-1998057955-A1 COMPOUNDS USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE SCHERING CORPORATION (US) 1998-12-23 WO disclosed
US-4988699-A Treatment of psychological disorders such as schizophrenia, as antipsychotic agents and hypotensive agents WARNER-LAMBERT COMPANY (US) 1991-01-29 US disclosed
US-4921994-A ANALGESICS, ANTIEMETICS PFIZER INC. (US) 1990-05-01 US disclosed
US-4831059-A ANTIEMETICS; DIARRHEA; CENTRAL NERVOUS SYSTEM PFIZER INC. (US) 1989-05-16 US disclosed
EP-0048572-B1 SUBSTITUTED 2-HYDROXYPHENYL CYCLOALKANES AND PHARMACEUTICAL COMPOSITIONS THEREOF PFIZER INC. (US) 1987-07-15 EP disclosed
US-4371720-A ANTIDIARRHEALS, ANTIEMETICS PFIZER INC. (US) 1983-02-01 US disclosed
EP-0048572-A2 Substituted 2-hydroxyphenyl cycloalkanes and pharmaceutical compositions thereof PFIZER INC. (US) 1982-03-31 EP disclosed
JP-S5692244-A PREPARATION OF 4-OXOCYCLOHEXYLACETIC ACID UBE IND LTD 1981-07-25 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441761-B2 Conjugation reagents and methods using 1,2-cyclohexanediones TNNI3, CHD1, TNNT2 ALDH1A1 1179/4885POLB 2875/4885MAPT 4699/4885
US-20250236632-A1 BETA-LACTAMASE INHIBITORS MGAM, GAA, LCT ALDH1A1 305/4885POLB 404/4885MAPT 4167/4885
US-20230295222-A1 Conjugation Reagents and Methods Using 1,2-Cyclohexanediones TNNI3, CHD1, TNNT2 ALDH1A1 1150/4885POLB 2499/4885MAPT 4752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.